Radical cystectomy for urothelial carcinoma of the bladder

An analysis of perioperative and survival outcome

Murugesan Manoharan, Rajinikanth Ayyathurai, Mark S. Soloway

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Objective To review the outcomes in a large group of patients treated with radical cystectomy (RC) for urothelial cancer (UC) of the bladder, by one surgical team. Patients and Methods In all, 504 patients had RC for UC of the bladder between 1992 and 2007; 432 met the inclusion criteria and were analysed for survival and disease recurrence. RESULTS Of the 432 patients, (mean age 69 years; mean follow-up 38 months, range 1-172), 240 (56%) and 179 (41%) had an ileal conduit and orthotopic neobladder for urinary diversion, respectively. The mortality rate within 30 days of RC was 2%; 105 (24%) patients developed local and/or distant recurrence with a mean interval of 13.6 months. The overall survival, recurrence-free survival (RFS) and disease-specific survival (DSS) at 5 years was 58%, 64% and 74%, respectively, and 43%, 62% and 68% at 10 years. The 5-year RFS and DSS for those with organ-confined, node-negative tumours was 81% and 91%, compared to 46% and 56% in those with extravesical extension and lymph node-negative tumours. The RFS and DSS of patients with lymph node metastasis at 5 years was 29% and 40%, respectively. Conclusion Our study reaffirms that RC with bilateral pelvic lymph node dissection offers a reasonable possibility of disease control at 5 years, with a DSS of 74%. However, there is a need for an earlier diagnosis and effective systemic therapy if additional gains in survival are to be delivered.

Original languageEnglish
Pages (from-to)1227-1232
Number of pages6
JournalBJU International
Volume104
Issue number9
DOIs
StatePublished - Nov 1 2009

Fingerprint

Cystectomy
Survival Analysis
Urinary Bladder
Carcinoma
Survival
Recurrence
Disease-Free Survival
Urinary Diversion
Urinary Bladder Neoplasms
Lymph Nodes
Lymph Node Excision
Early Diagnosis
Neoplasms
Neoplasm Metastasis
Mortality

Keywords

  • Bladder cancer
  • Radical cystectomy
  • Transitional cell carcinoma

ASJC Scopus subject areas

  • Urology

Cite this

Radical cystectomy for urothelial carcinoma of the bladder : An analysis of perioperative and survival outcome. / Manoharan, Murugesan; Ayyathurai, Rajinikanth; Soloway, Mark S.

In: BJU International, Vol. 104, No. 9, 01.11.2009, p. 1227-1232.

Research output: Contribution to journalArticle

Manoharan, Murugesan ; Ayyathurai, Rajinikanth ; Soloway, Mark S. / Radical cystectomy for urothelial carcinoma of the bladder : An analysis of perioperative and survival outcome. In: BJU International. 2009 ; Vol. 104, No. 9. pp. 1227-1232.
@article{59a283666e2b43f58dd29de605a00380,
title = "Radical cystectomy for urothelial carcinoma of the bladder: An analysis of perioperative and survival outcome",
abstract = "Objective To review the outcomes in a large group of patients treated with radical cystectomy (RC) for urothelial cancer (UC) of the bladder, by one surgical team. Patients and Methods In all, 504 patients had RC for UC of the bladder between 1992 and 2007; 432 met the inclusion criteria and were analysed for survival and disease recurrence. RESULTS Of the 432 patients, (mean age 69 years; mean follow-up 38 months, range 1-172), 240 (56{\%}) and 179 (41{\%}) had an ileal conduit and orthotopic neobladder for urinary diversion, respectively. The mortality rate within 30 days of RC was 2{\%}; 105 (24{\%}) patients developed local and/or distant recurrence with a mean interval of 13.6 months. The overall survival, recurrence-free survival (RFS) and disease-specific survival (DSS) at 5 years was 58{\%}, 64{\%} and 74{\%}, respectively, and 43{\%}, 62{\%} and 68{\%} at 10 years. The 5-year RFS and DSS for those with organ-confined, node-negative tumours was 81{\%} and 91{\%}, compared to 46{\%} and 56{\%} in those with extravesical extension and lymph node-negative tumours. The RFS and DSS of patients with lymph node metastasis at 5 years was 29{\%} and 40{\%}, respectively. Conclusion Our study reaffirms that RC with bilateral pelvic lymph node dissection offers a reasonable possibility of disease control at 5 years, with a DSS of 74{\%}. However, there is a need for an earlier diagnosis and effective systemic therapy if additional gains in survival are to be delivered.",
keywords = "Bladder cancer, Radical cystectomy, Transitional cell carcinoma",
author = "Murugesan Manoharan and Rajinikanth Ayyathurai and Soloway, {Mark S.}",
year = "2009",
month = "11",
day = "1",
doi = "10.1111/j.1464-410X.2009.08625.x",
language = "English",
volume = "104",
pages = "1227--1232",
journal = "BJU International",
issn = "1464-4096",
publisher = "Wiley-Blackwell",
number = "9",

}

TY - JOUR

T1 - Radical cystectomy for urothelial carcinoma of the bladder

T2 - An analysis of perioperative and survival outcome

AU - Manoharan, Murugesan

AU - Ayyathurai, Rajinikanth

AU - Soloway, Mark S.

PY - 2009/11/1

Y1 - 2009/11/1

N2 - Objective To review the outcomes in a large group of patients treated with radical cystectomy (RC) for urothelial cancer (UC) of the bladder, by one surgical team. Patients and Methods In all, 504 patients had RC for UC of the bladder between 1992 and 2007; 432 met the inclusion criteria and were analysed for survival and disease recurrence. RESULTS Of the 432 patients, (mean age 69 years; mean follow-up 38 months, range 1-172), 240 (56%) and 179 (41%) had an ileal conduit and orthotopic neobladder for urinary diversion, respectively. The mortality rate within 30 days of RC was 2%; 105 (24%) patients developed local and/or distant recurrence with a mean interval of 13.6 months. The overall survival, recurrence-free survival (RFS) and disease-specific survival (DSS) at 5 years was 58%, 64% and 74%, respectively, and 43%, 62% and 68% at 10 years. The 5-year RFS and DSS for those with organ-confined, node-negative tumours was 81% and 91%, compared to 46% and 56% in those with extravesical extension and lymph node-negative tumours. The RFS and DSS of patients with lymph node metastasis at 5 years was 29% and 40%, respectively. Conclusion Our study reaffirms that RC with bilateral pelvic lymph node dissection offers a reasonable possibility of disease control at 5 years, with a DSS of 74%. However, there is a need for an earlier diagnosis and effective systemic therapy if additional gains in survival are to be delivered.

AB - Objective To review the outcomes in a large group of patients treated with radical cystectomy (RC) for urothelial cancer (UC) of the bladder, by one surgical team. Patients and Methods In all, 504 patients had RC for UC of the bladder between 1992 and 2007; 432 met the inclusion criteria and were analysed for survival and disease recurrence. RESULTS Of the 432 patients, (mean age 69 years; mean follow-up 38 months, range 1-172), 240 (56%) and 179 (41%) had an ileal conduit and orthotopic neobladder for urinary diversion, respectively. The mortality rate within 30 days of RC was 2%; 105 (24%) patients developed local and/or distant recurrence with a mean interval of 13.6 months. The overall survival, recurrence-free survival (RFS) and disease-specific survival (DSS) at 5 years was 58%, 64% and 74%, respectively, and 43%, 62% and 68% at 10 years. The 5-year RFS and DSS for those with organ-confined, node-negative tumours was 81% and 91%, compared to 46% and 56% in those with extravesical extension and lymph node-negative tumours. The RFS and DSS of patients with lymph node metastasis at 5 years was 29% and 40%, respectively. Conclusion Our study reaffirms that RC with bilateral pelvic lymph node dissection offers a reasonable possibility of disease control at 5 years, with a DSS of 74%. However, there is a need for an earlier diagnosis and effective systemic therapy if additional gains in survival are to be delivered.

KW - Bladder cancer

KW - Radical cystectomy

KW - Transitional cell carcinoma

UR - http://www.scopus.com/inward/record.url?scp=70349977006&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349977006&partnerID=8YFLogxK

U2 - 10.1111/j.1464-410X.2009.08625.x

DO - 10.1111/j.1464-410X.2009.08625.x

M3 - Article

VL - 104

SP - 1227

EP - 1232

JO - BJU International

JF - BJU International

SN - 1464-4096

IS - 9

ER -